Lung cancer cells are able to take advantage of a person’s immune system, specifically T cells, to protect the tumor, according to new research recently published in Cancer Immunology Research.

Inhaled seralutinib demonstrated clinical activity in high-risk pulmonary arterial hypertension patients despite missing its primary phase 3 endpoint.

The interplay between host immunity, the microbiota, and cancer is a rapidly evolving area of immuno-oncology. An increasing body of evidence highlights the ...

GSK will acquire 35Pharma for $950 million, adding HS235, a new drug candidate targeting pulmonary hypertension affecting ...

GLP-1 drugs like Ozempic aren't just suppressing appetite — they may be rewiring the brain's reward system, and patients are spontaneously picking up hobbies, quitting alcohol, and signing up for 5Ks ...

When GSK’s new CEO Luke Miels told investors last month that “smart business development” is a key pillar for his strategy, he wasn’t lying. | Like Merck & Co.’s PAH drug Winrevair—which brought in $1 ...

Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary diseases HS235 offers potential to treat pulmonary ...

Adults with differentiated thyroid cancer who are using a GLP-1 for the treatment of diabetes or obesity do not have increased risk for cancer recurrence or progression vs. those not using a GLP-1, ...

Studies have demonstrated a critical role of the cytokines thymic stromal lymphopoietin (TSLP), IL-33, and IL-25, produced by epithelial and other cells at mucosal surfaces in response to a wide range ...

Stanford Medicine researchers have developed an experimental nasal vaccine that shielded mouse lungs for at least three months against a striking range of respiratory threats, from SARS-CoV-2 and ...

Dr Mark Kris examines new OS results for chemo plus osimertinib in EGFR-mutant NSCLC and how they align with survival gains seen previously with other EGFR TKIs.

Feb 23 (Reuters) - Gossamer Bio said on Monday its experimental drug for patients with a type of lung condition missed the ...